Evidence map›Paper›PMID 22318730›Full record

ArticleThe Journal of biological chemistry2012

Sequence-specific recruitment of heterochromatin protein 1 via interaction with Krüppel-like factor 11, a human transcription factor involved in tumor suppression and metabolic diseases.

Gwen Lomberk, Angela J Mathison, Adrienne Grzenda, Seungmae Seo, Cathrine J DeMars, Sumera I Ilyas, Juliana Bonilla-Velez, Ezequiel Calvo, Martin E Fernandez-Zapico, Juan Iovanna and 2 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Milestones in transcription and chromatin published in theThe Journal of biological chemistry · 2019
    Review
  16. Krüppel-like factors and vascular wall homeostasis.Journal of molecular cell biology · 2017
    Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Gwen LomberkDepartment of Biochemistry and Molecular Biology, Laboratory of Epigenetics and Chromatin Dynamics, GIH Division, Mayo Clinic, Rochester, Minnesota 55905, USA. lomberk.gwen@mayo.edu
Angela J Mathison
Adrienne Grzenda
Seungmae Seo
Cathrine J DeMars
Sumera I Ilyas
Juliana Bonilla-Velez
Ezequiel Calvo
Martin E Fernandez-Zapico
Juan Iovanna
Navtej S Buttar
Raul Urrutia
Mayo Clinic · USInserm · FR

Funding

Tissue CoreP50CA102701 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M. · 2004 to 2018
$32.7M
PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI Nicholas F. LaRusso · 2009 to 2026
$22.2M
ZINC FINGER GENES AND PANCREATIC CELL GROWTHR01DK052913 · NIDDK · MEDICAL COLLEGE OF WISCONSIN · PI LOMBERK, GWEN, URRUTIA, RAUL A. · 1998 to 2023
$7.0M
Role of Vav1 protooncogene in pancreatic cancerP20CA102701 · NCI · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI URRUTIA, RAUL A · 2003 to 2003
$1.5M
Tumor Microenvironment/Angiogenesis Training GrantT32CA148073 · NCI · MAYO CLINIC ROCHESTER · PI MC NIVEN, MARK A. · 2010 to 2014
$1.2M
Growth Regulatory Mechanisms of KLF in Barrett's EpitheliumK08DK076845 · NIDDK · MAYO CLINIC ROCHESTER · PI BUTTAR, NAVTEJ S · 2007 to 2011
$686k
The Role of Zinc Finger Genes in Pancreatic Cell GrowthR56DK052913 · NIDDK · MAYO CLINIC ROCHESTER · PI URRUTIA, RAUL A. · 2008 to 2008
$291k
Combinational Chemoprevention of Esophageal Adenocarcin*R03CA110022 · NCI · MAYO CLINIC · PI BUTTAR, NAVTEJ S · 2004 to 2005
$148k
NCI NIH HHS CA102701NCI NIH HHS CA110022-01NCI NIH HHS P20 CA102701NCI NIH HHS P50 CA102701NCI NIH HHS R03 CA110022NCI NIH HHS T32 CA148073NCI NIH HHS T32-CA148073NIDDK NIH HHS DK52913NIDDK NIH HHS DK76845NIDDK NIH HHS K08 DK076845NIDDK NIH HHS P30 DK084567NIDDK NIH HHS P30DK084567NIDDK NIH HHS R01 DK052913NIDDK NIH HHS R56 DK052913
6 · The paper itself

Abstract

Heterochromatin protein 1 (HP1) proteins are "gatekeepers" of epigenetic gene silencing that is mediated by lysine 9 of histone H3 methylation (H3K9me). Current knowledge supports a paradigm whereby HP1 proteins achieve repression by binding to H3K9me marks and interacting to H3K9 histone methyltransferases (HMTs), such as SUV39H1, which methylate this residue on adjacent nucleosomes thereby compacting chromatin and silencing gene expression. However, the mechanism underlying the recruitment of this epigenetic regulator to target gene promoters remains poorly characterized. In the current study, we reveal for the first time a mechanism whereby HP1 is recruited to promoters by a well characterized Krüppel-like transcription factor (KLF), in a sequence-specific manner, to mediate complex biological phenomena. A PXVXL HP1-interacting domain identified at position 487-491 of KLF11 mediates the binding of HP1α and KLF11 in vitro and in cultured cells. KLF11 also recruits HP1α and its histone methyltransferase, SUV39H1, to promoters to limit KLF11-mediated gene activation. Indeed, a KLF11ΔHP1 mutant derepresses KLF11-regulated cancer genes, by inhibiting HP1-SUV39H1 recruitment, decreasing H3K9me3, while increasing activation-associated marks. Biologically, impairment of KLF11-mediated HP1-HMT recruitment abolishes tumor suppression, providing direct evidence that HP1-HMTs act in a sequence-specific manner to achieve this function rather than its well characterized binding to methylated chromatin without intermediary. Collectively, these studies reveal a novel role for HP1 as a cofactor in tumor suppression, expand our mechanistic understanding of a KLF associated to human disease, and outline cellular and biochemical mechanisms underlying this phenomenon, increasing the specificity of targeting HP1-HMT complexes to gene promoters.

Indexed as

AnimalsApoptosis Regulatory ProteinsCell Cycle ProteinsCell DeathCell DivisionCell Line, TumorCellular SenescenceCHO CellsChromatinChromobox Protein Homolog 5Chromosomal Proteins, Non-HistoneCricetinaeFemaleGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansApoptosis Regulatory ProteinsCBX5 protein, humanCell Cycle ProteinsChromatinChromobox Protein Homolog 5Chromosomal Proteins, Non-HistoneCXCR4 protein, humanKLF11 protein, humanReceptors, CXCR4Repressor Proteins

Identifiers

PMID22318730
PMCPMC3339955
OpenAlexW2035476180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.